CH695185A9 - Compositions pharmaceutiques injectables contenant de la pipéracilline et du tazobactame et procédé pour leur production. - Google Patents

Compositions pharmaceutiques injectables contenant de la pipéracilline et du tazobactame et procédé pour leur production. Download PDF

Info

Publication number
CH695185A9
CH695185A9 CH00641/04A CH6412004A CH695185A9 CH 695185 A9 CH695185 A9 CH 695185A9 CH 00641/04 A CH00641/04 A CH 00641/04A CH 6412004 A CH6412004 A CH 6412004A CH 695185 A9 CH695185 A9 CH 695185A9
Authority
CH
Switzerland
Prior art keywords
tazobactam
production
pharmaceutical compositions
compositions containing
injectable pharmaceutical
Prior art date
Application number
CH00641/04A
Other languages
English (en)
French (fr)
Other versions
CH695185A5 (fr
Inventor
Mahdi Bakir Fawzi
Jonathan Marc Cohen
Syed Muzafar Shah
Christian Luther Ofslager
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH695185(A9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CH695185A5 publication Critical patent/CH695185A5/fr
Publication of CH695185A9 publication Critical patent/CH695185A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CH00641/04A 2003-04-14 2004-04-13 Compositions pharmaceutiques injectables contenant de la pipéracilline et du tazobactame et procédé pour leur production. CH695185A9 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46280803P 2003-04-14 2003-04-14

Publications (2)

Publication Number Publication Date
CH695185A5 CH695185A5 (fr) 2006-01-13
CH695185A9 true CH695185A9 (fr) 2006-02-28

Family

ID=32326726

Family Applications (1)

Application Number Title Priority Date Filing Date
CH00641/04A CH695185A9 (fr) 2003-04-14 2004-04-13 Compositions pharmaceutiques injectables contenant de la pipéracilline et du tazobactame et procédé pour leur production.

Country Status (34)

Country Link
US (3) US7498312B2 (https=)
EP (1) EP1468697B1 (https=)
JP (1) JP4644659B2 (https=)
KR (1) KR100824554B1 (https=)
CN (1) CN1802179B (https=)
AR (1) AR043863A1 (https=)
AT (1) ATE381947T1 (https=)
AU (1) AU2004229407B2 (https=)
BR (1) BRPI0409450B8 (https=)
CA (1) CA2464258C (https=)
CH (1) CH695185A9 (https=)
CL (1) CL2004000782A1 (https=)
CO (1) CO5700796A2 (https=)
CR (2) CR8035A (https=)
CY (1) CY1108064T1 (https=)
DE (1) DE602004010862T2 (https=)
DK (1) DK1468697T3 (https=)
EC (1) ECSP056100A (https=)
ES (1) ES2298672T3 (https=)
FR (1) FR2853547B1 (https=)
GB (1) GB2400557B (https=)
IL (1) IL171337A (https=)
MX (1) MXPA05010996A (https=)
MY (1) MY139099A (https=)
NO (1) NO20054789L (https=)
NZ (1) NZ543005A (https=)
PL (1) PL1468697T3 (https=)
PT (1) PT1468697E (https=)
RU (2) RU2322980C2 (https=)
SA (1) SA04250119B1 (https=)
SI (1) SI1468697T1 (https=)
TW (1) TWI308069B (https=)
WO (1) WO2004091666A1 (https=)
ZA (1) ZA200508315B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110209B2 (en) 2002-12-20 2012-02-07 Xeris Pharmaceuticals Inc. Intracutaneous injection
EP1468697B1 (en) * 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
KR20070110256A (ko) * 2004-10-14 2007-11-16 와이어쓰 유산나트륨 희석제 내에 피페라실린, 타조박탐 및아미노카르복실산을 함유하는 조성물
PT1841432E (pt) * 2004-12-02 2010-10-25 Venus Remedies Ltd Composições para combater a resistência aos antibióticos mediada pela beta-lactamase usando inibidores da betalactamase úteis para injecção
ES2284318B1 (es) * 2005-04-13 2008-11-01 Labiana Development, S.L. Procedimiento de obtencion de una mezcla en polvo de una sal sodica de piperaciclina y tazobactama, util para su administracion por via inyectable.
ITMI20051630A1 (it) 2005-09-02 2007-03-03 Acs Dobfar Spa Formulazione farmaceutica sterile iniettabile contenente almeno due principi attivi
CN101129381B (zh) * 2006-08-25 2012-02-01 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN101129382B (zh) * 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
CN102210679B (zh) * 2006-08-25 2013-03-13 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN102441169A (zh) * 2006-08-25 2012-05-09 天津和美生物技术有限公司 含β-内酰胺类抗生素和离子螯合剂的抗生素复方
CN1927201B (zh) * 2006-08-25 2011-06-01 天津和美生物技术有限公司 含哌拉西林的抗生素复方
CN101129383B (zh) * 2006-08-25 2014-04-02 天津和美生物技术有限公司 含氨基糖苷类抗生素的抗生素复方
CN101265263B (zh) * 2008-05-12 2010-06-02 海南百那医药发展有限公司 哌拉西林钠他唑巴坦钠复方注射剂的生产方法
JP5639471B2 (ja) * 2008-07-28 2014-12-10 惠三 山口 感染症治療効果増強剤
JP5852316B2 (ja) * 2010-03-30 2016-02-03 富山化学工業株式会社 ピペラシリン含有懸濁液の製造法
WO2012012460A1 (en) 2010-07-19 2012-01-26 Xeris Pharmaceuticals, Inc. Stable glucagon formulations for the treatment of hypoglycemia
BR112013012735B1 (pt) 2010-11-25 2021-11-23 Allecra Therapeutics Gmbh Composição farmacêutica inibidora de ss-lactamase
EP2683364B1 (en) 2011-03-10 2017-01-18 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
WO2013067022A1 (en) 2011-10-31 2013-05-10 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
EP3431092A1 (en) 2012-03-26 2019-01-23 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) * 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
KR101816798B1 (ko) * 2012-10-19 2018-01-10 주식회사유한양행 피페라실린 또는 그의 염, 타조박탐 또는 그의 염 및 덱사메타손 포스페이트 또는 그의 염을 포함하는 국소투여용 약학 조성물
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US9320740B2 (en) 2013-03-15 2016-04-26 Merck Sharp & Dohme Corp. Ceftolozane-tazobactam pharmaceutical compositions
CN110279698B (zh) 2013-03-15 2022-10-28 默沙东有限责任公司 头孢特咯瓒抗生素组合物
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
EP3185932A1 (en) 2014-08-06 2017-07-05 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
KR20170067709A (ko) * 2014-10-08 2017-06-16 사와이세이야쿠 가부시키가이샤 동결 건조 제제의 제조 방법
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
AU2017242135A1 (en) * 2016-03-31 2017-11-02 Wockhardt Limited Antibacterial compositions
WO2018025248A1 (en) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Edta injection and process for making the same
US11020403B2 (en) 2017-06-02 2021-06-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
US11110054B2 (en) * 2018-05-09 2021-09-07 Slayback Pharma Llc Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate
CN112618486B (zh) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 一种注射用混悬油剂及其制备方法
CN113209030B (zh) * 2021-04-27 2023-04-25 海南通用康力制药有限公司 哌拉西林钠他唑巴坦钠无菌粉针剂的制备方法
WO2025253343A1 (en) * 2024-06-06 2025-12-11 Chandan Chopra AN ANTIBIOTIC COMPOSITION OF A PENICILLIN, A β-LACTAMASE INHIBITOR AND AN ION-CHELATING AGENT
CN119367287B (zh) * 2024-12-27 2025-03-28 成都硕德药业有限公司 一种重酒石酸去甲肾上腺素注射液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477452A (en) 1981-03-26 1984-10-16 American Cyanamid Company Composition of matter comprising a lyophilized preparation of a penicillin derivative
US4534977A (en) 1981-03-26 1985-08-13 American Cyanamid Company Composition of matter comprising a low bulk density lyophilized preparation of Sodium Piperacillin
US4562073A (en) 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US5763480A (en) * 1994-02-14 1998-06-09 The Jewish Hospital Of St. Louis Inhibitors of cell-medicated disorders
US5580856A (en) * 1994-07-15 1996-12-03 Prestrelski; Steven J. Formulation of a reconstituted protein, and method and kit for the production thereof
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6207661B1 (en) * 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
EP1499341A4 (en) * 2002-04-18 2010-10-27 Univ Iowa Res Found METHOD FOR INHIBITING AND TREATING BACTERIAL BIOFILMS WITH METAL CHELATE IMAGES
EP1468697B1 (en) * 2003-04-14 2007-12-26 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
WO2004098643A1 (en) * 2003-04-14 2004-11-18 Wyeth Holdings Corporation Compositions containing piperacillin and tazobactam useful for injection
US6900184B2 (en) 2003-04-14 2005-05-31 Wyeth Holdings Corporation Compositions containing pipercillin and tazobactam useful for injection

Also Published As

Publication number Publication date
FR2853547A1 (fr) 2004-10-15
DE602004010862T2 (de) 2009-01-02
EP1468697A1 (en) 2004-10-20
DK1468697T3 (da) 2008-04-14
JP4644659B2 (ja) 2011-03-02
WO2004091666A8 (en) 2005-11-10
ZA200508315B (en) 2008-04-30
TW200503758A (en) 2005-02-01
KR20060014375A (ko) 2006-02-15
CH695185A5 (fr) 2006-01-13
NZ543005A (en) 2009-03-31
MXPA05010996A (es) 2005-12-12
CL2004000782A1 (es) 2005-03-04
US20090176720A1 (en) 2009-07-09
BRPI0409450A (pt) 2006-05-02
WO2004091666A1 (en) 2004-10-28
HK1069775A1 (en) 2005-06-03
RU2007142454A (ru) 2009-05-27
GB0407853D0 (en) 2004-05-12
GB2400557B (en) 2005-06-15
TWI308069B (en) 2009-04-01
NO20054789D0 (no) 2005-10-18
KR100824554B1 (ko) 2008-04-24
ECSP056100A (es) 2006-03-01
CN1802179A (zh) 2006-07-12
AU2004229407B2 (en) 2010-04-22
DE602004010862D1 (de) 2008-02-07
US20060234995A1 (en) 2006-10-19
CY1108064T1 (el) 2014-02-12
BRPI0409450B1 (pt) 2016-07-12
SA04250119B1 (ar) 2008-03-30
CO5700796A2 (es) 2006-11-30
JP2006523695A (ja) 2006-10-19
IL171337A (en) 2011-03-31
MY139099A (en) 2009-08-28
US20110166091A1 (en) 2011-07-07
AU2004229407A1 (en) 2004-10-28
CA2464258A1 (en) 2004-10-14
SI1468697T1 (sl) 2008-04-30
CR8035A (es) 2006-05-30
ES2298672T3 (es) 2008-05-16
RU2005135135A (ru) 2006-06-10
US7498312B2 (en) 2009-03-03
GB2400557A (en) 2004-10-20
CA2464258C (en) 2005-06-07
EP1468697B1 (en) 2007-12-26
PT1468697E (pt) 2008-03-05
CN1802179B (zh) 2011-09-14
BRPI0409450B8 (pt) 2021-05-25
US7915229B2 (en) 2011-03-29
AR043863A1 (es) 2005-08-17
NO20054789L (no) 2005-12-13
ATE381947T1 (de) 2008-01-15
RU2322980C2 (ru) 2008-04-27
US8133883B2 (en) 2012-03-13
CR9792A (es) 2008-09-23
PL1468697T3 (pl) 2008-05-30
FR2853547B1 (fr) 2006-08-04

Similar Documents

Publication Publication Date Title
CH695185A9 (fr) Compositions pharmaceutiques injectables contenant de la pipéracilline et du tazobactame et procédé pour leur production.
MA26743A1 (fr) Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2827604B1 (fr) Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2816938B1 (fr) Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
EP2331074A4 (en) GRANULATE, PROCESS FOR ITS MANUFACTURE AND PHARMACEUTICAL PRODUCTS THEREWITH
DZ2773A1 (fr) Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB2402063B (en) Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof
DZ3000A1 (fr) Macrolides nouveaux, procédé pour leur préparationet compositions pharmaceutiques les contenant.
ATE407921T1 (de) Neues verfahren zur herstellung und eine neue kristallform des agomelatins sowie pharmazeutische zusammensetzungen, die diese enthalten
EA200702674A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
CH689805A8 (fr) Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
FR2794742B1 (fr) Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2810320B1 (fr) Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2805536B1 (fr) Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
ATE513820T1 (de) Neue benzamidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
ATE471930T1 (de) 3-aminocarbazolverbindungen, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu deren herstellung
EP1624859A4 (en) METHOD FOR PRODUCING THERMOFORMED COMPOSITIONS WITH ACRYLIC POLYMER BINDERS, PHARMACEUTICAL DOSAGE FORMS, AND METHOD FOR THE PRODUCTION THEREOF
EP1781629A4 (en) NEW BENZAMIDINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THEM
FR2869611B1 (fr) Derives de l'acide hexenoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
FR2818643B1 (fr) Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques que les contiennent
FR2824828B1 (fr) Nouveaux derives de piperidinecarboxamide, un procede pour leur preparation et les compositions pharmaceutiques les contenant
FR2830531B1 (fr) Acides naphtylsulfoniques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
DE602007012845D1 (de) Neue dipeptidylpeptidase-iv-inhibitoren und verfahren zur ihrer herstellung und pharmazeutische zusammensetzung, die diese enthalten

Legal Events

Date Code Title Description
PK Correction

Free format text: CORRECTION DE TOUT LE DOCUMENT

PFA Name/firm changed

Owner name: WYETH HOLDINGS CORPORATION

Free format text: WYETH HOLDINGS CORPORATION#FIVE GIRALDA FARMS#MADISON, NJ 07940-0874 (US) -TRANSFER TO- WYETH HOLDINGS CORPORATION#FIVE GIRALDA FARMS#MADISON, NJ 07940-0874 (US)

PL Patent ceased